Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
30.00
+0.25 (0.84%)
Nov 20, 2024, 4:00 PM EST - Market closed
Collegium Pharmaceutical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 599.25 | 566.77 | 463.93 | 276.87 | 310.02 | 296.7 | Upgrade
|
| Revenue Growth (YoY) | 9.62% | 22.17% | 67.56% | -10.69% | 4.49% | 5.81% | Upgrade
|
| Cost of Revenue | 79.91 | 79.72 | 78.61 | 59.07 | 69.5 | 178.91 | Upgrade
|
| Gross Profit | 519.33 | 487.05 | 385.33 | 217.8 | 240.52 | 117.79 | Upgrade
|
| Selling, General & Admin | 157.28 | 150.71 | 141.59 | 118.96 | 113.83 | 116.45 | Upgrade
|
| Research & Development | - | - | 3.98 | 9.45 | 9.77 | 10.34 | Upgrade
|
| Operating Expenses | 301.62 | 296.47 | 277.04 | 195.59 | 184.28 | 141.54 | Upgrade
|
| Operating Income | 217.71 | 190.58 | 108.29 | 22.21 | 56.23 | -23.75 | Upgrade
|
| Interest Expense | -70.6 | -83.34 | -63.21 | -21.01 | -28.88 | -0.91 | Upgrade
|
| Interest & Investment Income | 16.47 | 15.62 | 1.05 | 0.01 | 0.23 | 1.94 | Upgrade
|
| EBT Excluding Unusual Items | 163.58 | 122.85 | 46.12 | 1.2 | 27.58 | -22.72 | Upgrade
|
| Merger & Restructuring Charges | -21.19 | -15.12 | -70.18 | -4.58 | - | - | Upgrade
|
| Asset Writedown | - | - | -4.79 | - | - | - | Upgrade
|
| Legal Settlements | - | -8.5 | - | - | - | - | Upgrade
|
| Other Unusual Items | -14.38 | -23.5 | - | - | - | - | Upgrade
|
| Pretax Income | 128.01 | 75.73 | -28.85 | -3.37 | 27.58 | -22.72 | Upgrade
|
| Income Tax Expense | 39.42 | 27.58 | -3.85 | -74.89 | 0.83 | - | Upgrade
|
| Net Income | 88.59 | 48.16 | -25 | 71.52 | 26.75 | -22.72 | Upgrade
|
| Net Income to Common | 88.59 | 48.16 | -25 | 71.52 | 26.75 | -22.72 | Upgrade
|
| Net Income Growth | 882.63% | - | - | 167.33% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 32 | 34 | 34 | 35 | 34 | 33 | Upgrade
|
| Shares Outstanding (Diluted) | 46 | 42 | 34 | 41 | 35 | 33 | Upgrade
|
| Shares Change (YoY) | 31.56% | 23.53% | -17.58% | 16.77% | 5.07% | 1.52% | Upgrade
|
| EPS (Basic) | 2.74 | 1.43 | -0.74 | 2.05 | 0.78 | -0.68 | Upgrade
|
| EPS (Diluted) | 2.16 | 1.29 | -0.74 | 1.86 | 0.76 | -0.68 | Upgrade
|
| EPS Growth | 757.11% | - | - | 144.25% | - | - | Upgrade
|
| Free Cash Flow | 192.43 | 274.29 | 122.61 | 101.61 | 88.4 | 21.35 | Upgrade
|
| Free Cash Flow Per Share | 4.21 | 6.56 | 3.62 | 2.48 | 2.51 | 0.64 | Upgrade
|
| Gross Margin | 86.66% | 85.93% | 83.06% | 78.66% | 77.58% | 39.70% | Upgrade
|
| Operating Margin | 36.33% | 33.63% | 23.34% | 8.02% | 18.14% | -8.00% | Upgrade
|
| Profit Margin | 14.78% | 8.50% | -5.39% | 25.83% | 8.63% | -7.66% | Upgrade
|
| Free Cash Flow Margin | 32.11% | 48.40% | 26.43% | 36.70% | 28.51% | 7.19% | Upgrade
|
| EBITDA | 365.82 | 339.83 | 242.44 | 91.12 | 117.78 | -8.27 | Upgrade
|
| EBITDA Margin | 61.05% | 59.96% | 52.26% | 32.91% | 37.99% | -2.79% | Upgrade
|
| D&A For EBITDA | 148.11 | 149.26 | 134.15 | 68.92 | 61.55 | 15.48 | Upgrade
|
| EBIT | 217.71 | 190.58 | 108.29 | 22.21 | 56.23 | -23.75 | Upgrade
|
| EBIT Margin | 36.33% | 33.63% | 23.34% | 8.02% | 18.14% | -8.00% | Upgrade
|
| Effective Tax Rate | 30.79% | 36.41% | - | - | 3.01% | - | Upgrade
|
| Advertising Expenses | - | 7.41 | 11.74 | 4.19 | 5.37 | 9.53 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.